Type I interferons in anticancer immunity

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Virus interference. I. the interferon

Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,520

Immunogenic cell death in cancer and infectious disease

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119

Inflammation and tumor progression: signaling pathways and targeted intervention

Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 3,058

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,906

NF-κB, inflammation, immunity and cancer: coming of age

Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819

RIG-I-like receptors: their regulation and roles in RNA sensing

Rehwinkel, J., & Gack, M. U. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0288-3 · Cited by 1,770

Autophagy in major human diseases

Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530

Immunogenic cell stress and death

Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Buqué, A., Chan, T. A.-T., Coukos, G., Demaria, S., Deutsch, É., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,210

Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy

Lv, M., Chen, M., Zhang, R., Zhang, W., Wang, C., Zhang, Y., Wei, X., Guan, Y., Liu, J., Feng, K., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00395-4 · Cited by 1,040

Harnessing innate immunity in cancer therapy

Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944

A STING-activating nanovaccine for cancer immunotherapy

Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 907

Autophagy in inflammation, infection, and immunometabolism

Deretic, V. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.018 · Cited by 862

Clinical significance of tumor-infiltrating lymphocytes in breast cancer

Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 854

Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis

Ma, Q., Xing, C., Long, W., Wang, H. Y., Liu, Q., & Wang, R. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1434-3 · Cited by 767

Control of Metastasis by NK Cells

López‐Soto, A., Gonzalez, S. R., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 744

Necroptosis: Mechanisms and Relevance to Disease

Galluzzi, L., Kepp, O., Chan, F. K.-M., & Kroemer, G. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100247 · Cited by 740

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 736

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

Yang, R., Sun, L., Li, C.-F., Wang, Y.-H., Yao, J., Li, H., Yan, M., Chang, W., Hsu, J.-M., Cha, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21099-2 · Cited by 656

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

Stanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 647

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy

Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 618

Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment

Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A., Johnson, S. B., Schwarz, B., Bohrnsen, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.019 · Cited by 604

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends

Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598

Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS

Zhang, W., Wang, G., Xu, Z., Tu, H.-Q., Hu, F., Dai, J., Chang, Y., Chen, Y., Lu, Y., Zeng, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.003 · Cited by 606

Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease

Roy, E. R., Wang, B., Wan, Y.-W., Chiu, G., Cole, A., Yin, Z., Propson, N. E., Xu, Y., Jankowsky, J. L., Liu, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133737 · Cited by 563

Linking cellular stress responses to systemic homeostasis

Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 556

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Nakamura, K., & Smyth, M. J. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 530

Targeting cytokine and chemokine signaling pathways for cancer therapy

Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528

Type I Interferon in Chronic Virus Infection and Cancer

Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 490

Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities

Cheong, J. E., & Sun, L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 504

TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells

Balka, K. R., Louis, C., Saunders, T. L., Smith, A. M., Calleja, D. J., D’Silva, D. B., Moghaddas, F., Tailler, M., Lawlor, K. E., Zhan, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.056 · Cited by 506

The host STING pathway at the interface of cancer and immunity

Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487

Dendritic cells in cancer: the role revisited

Veglia, F., & Gabrilovich, D. I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.002 · Cited by 464

The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor FamilyPreprint

Negishi, H., Taniguchi, T., & Yanai, H. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028423 · Cited by 467

Interferons α and β in cancer: therapeutic opportunities from new insights

Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 428

Calreticulin and cancer

Fucikova, J. P., Špíšek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 422

Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions

Andersson, A., Larsson, L., Stenbeck, L., Salmén, F., Ehinger, A., Wu, S. Z., Al-Eryani, G., Roden, D., Swarbrick, A., Borg, Å., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26271-2 · Cited by 404

STING Agonists as Cancer Therapeutics

Amouzegar, A., Chelvanambi, M., Filderman, J. N., Storkus, W. J., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13112695 · Cited by 419

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP

Zhou, Y., Fei, M., Zhang, G., Liang, W., Lin, W., Wu, Y., Piskol, R., Ridgway, J. B., McNamara, E., Huang, H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.01.014 · Cited by 406

First oncolytic virus approved for melanoma immunotherapy

Pol, J. G., Kroemer, G., & Galluzzi, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1115641 · Cited by 395

Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity

Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity · doi:10.1016/j.immuni.2021.10.020 · Cited by 372

Trisomy 21 consistently activates the interferon response

Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., et al. (2016) · eLife · doi:10.7554/elife.16220 · Cited by 362

Caspases Connect Cell-Death Signaling to Organismal Homeostasis

Galluzzi, L., López-Soto, A., Kumar, S., & Kroemer, G. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.020 · Cited by 350

Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss

Liu, H., Golji, J., Brodeur, L. K., Chung, F. S., Chen, J. T., deBeaumont, R. S., Bullock, C., Jones, M. D., Kerr, G., Li, L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0302-5 · Cited by 359

Three decades of messenger RNA vaccine development

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342

Emerging roles of p53 and other tumour-suppressor genes in immune regulation

Muñoz‐Fontela, C., Mandinova, A., Aaronson, S. A., & Lee, S. W. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.99 · Cited by 344

Type 1 Interferons Induce Changes in Core Metabolism that Are Critical for Immune Function

Wu, D., Sanin, D. E., Everts, B., Chen, Q., Qiu, J., Buck, M. D., Patterson, A. E., Smith, A. M., Chang, C., Liu, Z., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.006 · Cited by 331

Prolonged activation of innate immune pathways by a polyvalent STING agonist

Li, S., Luo, M., Wang, Z., Feng, Q., Wilhelm, J., Wang, X., Li, W., Wang, J., Cholka, A., Fu, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00675-9 · Cited by 327

Manganese salts function as potent adjuvants

Zhang, R., Wang, C., Guan, Y., Wei, X., Sha, M., Yi, M., Jing, M., Lv, M., Guo, W., Xu, J., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00669-w · Cited by 329

DNA Damage and Cancer Immunotherapy: A STING in the Tale

Reisländer, T., Groelly, F. J., & Tarsounas, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.026 · Cited by 325

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

Gato, M., Zuazo, M., Arasanz, H., Ibáñez-Vea, M., de Lorenzo, L., Fernández-Hinojal, G., Vera, R., Smerdou, C., Martišová, E., Arozarena, I., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.075 · Cited by 310

Type I interferon-mediated tumor immunity and its role in immunotherapy

Yu, R., Zhu, B., & Chen, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04219-z · Cited by 309

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Zheng, M., Huang, J., Tong, A., & Yang, H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.007 · Cited by 302

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 308

The intracellular signalosome of PD-L1 in cancer cells

Escors, D., Gato, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. T. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 308

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

Bourgeois‐Daigneault, M., Roy, D. G., Aitken, A. S., El-Sayes, N., Martin, N. T., Varette, O., Falls, T. J., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 295

Trial watch: STING agonists in cancer therapy

Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289

Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook

Horvath, L., Thienpont, B., Zhao, L., Wolf, D. G. F., & Pircher, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01260-z · Cited by 288

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer

Sato-Kaneko, F., Yao, S., Ahmadi, A., Zhang, S. S., Hosoya, T., Kaneda, M. M., Varner, J. A., Pu, M., Messer, K. S., Guiducci, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93397 · Cited by 291

Direct Antiviral Mechanisms of Interferon-Gamma

Kang, S., Brown, H. M., & Hwang, S. (2018) · Immune Network · doi:10.4110/in.2018.18.e33 · Cited by 280

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

Ni, Q., Zhang, F., Liu, Y., Wang, Z., Yu, G., Liang, B., Niu, G., Su, T., Zhu, G., Lu, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaw6071 · Cited by 280

Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend

Locy, H., de Mey, S., de Mey, W., Ridder, M. D., Thielemans, K., & Maenhout, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02909 · Cited by 282

Estrogen Receptor Signaling in the Immune System

Chakraborty, B., Byemerwa, J. K., Krebs, T., Lim, F., Chang, C., & McDonnell, D. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac017 · Cited by 283

Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy

Hou, Y., Liang, H. L., Rao, E., Zheng, W., Huang, X., Deng, L., Zhang, Y., Yu, X., Xu, M. M., Mauceri, H. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.008 · Cited by 278

NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists

Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz2738 · Cited by 268

The good and the bad faces of STAT1 in solid tumours

Meissl, K., Macho‐Maschler, S., Müller, M. M., & Strobl, B. (2015) · Cytokine · doi:10.1016/j.cyto.2015.11.011 · Cited by 272

Activating a collaborative innate-adaptive immune response to control metastasis

Sun, L., Kees, T., Almeida, A. S., Liu, B., He, X., Ng, D. C., Han, X., Spector, D. L., McNeish, I. A., Gimotty, P. A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.005 · Cited by 268

STING activation in cancer immunotherapy

Su, T., Zhang, Y. L., Valerie, K. C., Wang, X., Lin, S., & Zhu, G. (2019) · Theranostics · doi:10.7150/thno.37574 · Cited by 262

Trial watch

Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 260

cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity

Wang, Z., Chen, J., Hu, J., Zhang, H., Xu, F., He, W., Wang, X., Li, M., Lu, W., Zeng, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127471 · Cited by 253

Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer

Ma, Z., Li, X., Mao, Y., Chen, W., Huang, Z., Li, G., Yin, J., Liang, X., & Liu, Z. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.005 · Cited by 256

Cytosolic DNA Sensing in Organismal Tumor Control

Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment

Katlinski, K. V., Gui, J., Katlinskaya, Y. V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C. J., Beiting, D. P., Girondo, M. A., Peck, A. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.004 · Cited by 257

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors

Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 245

Trial watch: TLR3 agonists in cancer therapy

Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239

Cell membrane coated-nanoparticles for cancer immunotherapy

Zeng, Y., Li, S., Zhang, S., Wang, L., Yuan, H., & Hu, F. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.023 · Cited by 238

AIM2 in health and disease: Inflammasome and beyond

Kumari, P. H., Russo, A. J., Shivcharan, S., & Rathinam, V. A. K. (2020) · Immunological Reviews · doi:10.1111/imr.12903 · Cited by 250

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Gujar, S. A., Pol, J. G., Kim, Y., Lee, P. W. K., & Kroemer, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 234

The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer

Storozynsky, Q. T., & Hitt, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228877 · Cited by 236

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Smith, M. M., García-Martínez, E., Pitter, M. R., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526250 · Cited by 237

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 + T cells

Wang, S., Campos, J. S., Gallotta, M., Gong, M., Crain, C., Naik, E., Coffman, R. L., & Guiducci, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608555113 · Cited by 235

Vaccine adjuvants as potential cancer immunotherapeutics

Temizoz, B., Kuroda, E., & Ishii, K. J. (2016) · International Immunology · doi:10.1093/intimm/dxw015 · Cited by 236

Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy

Zhang, Q., Green, M. D., Lang, X., Lazarus, J., Parsels, J. D., Wei, S., Parsels, L. A., Shi, J., Ramnath, N., Wahl, D. R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0761 · Cited by 229

NEMO–IKKβ Are Essential for IRF3 and NF-κB Activation in the cGAS–STING Pathway

Fang, R., Wang, C., Jiang, Q., Lv, M., Gao, P., Yu, X., Mu, P., Zhang, R., Bi, S., Feng, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700699 · Cited by 227

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs

Brown, M. C., Holl, E. K., Boczkowski, D., Dobrikova, E. Y., Mosaheb, M., Chandramohan, V., Bigner, D. D., Gromeier, M., & Nair, S. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4220 · Cited by 228

Targeting innate immune pathways for cancer immunotherapy

Cao, L. L., & Kagan, J. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.018 · Cited by 234

Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment

Baharom, F., Ramirez-Valdez, R. A., Khalilnezhad, A., Khalilnezhad, S., Dillon, M., Hermans, D., Fussell, S. C., Tobin, K. K. S., Dutertre, C., Lynn, G. M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.10.006 · Cited by 220

An origin of the immunogenicity of in vitro transcribed RNA

Mu, X., Greenwald, E., Ahmad, S., & Hur, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky177 · Cited by 218

Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression

Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216

Immunogenic Cell Death Augmented by Manganese Zinc Sulfide Nanoparticles for Metastatic Melanoma Immunotherapy

Li, Z., Chu, Z., Yang, J., Qian, H., Xu, J., Chen, B., Tian, T., Chen, H., Xu, Y., & Wang, F. (2022) · ACS Nano · doi:10.1021/acsnano.2c08013 · Cited by 217

pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation

Nuhn, L., Vanparijs, N., Beuckelaer, A. D., Lybaert, L., Verstraete, G., Deswarte, K., Lienenklaus, S., Shukla, N. M., Salyer, A. C. D., Lambrecht, B. N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600816113 · Cited by 215

cGAS–STING and Cancer: Dichotomous Roles in Tumor Immunity and Development

Ng, K. W., Marshall, E. A., Bell, J. C., & Lam, W. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.013 · Cited by 219

Origin and Consequences of Necroinflammation

Sarhan, M., Land, W. G., Tonnus, W., Hugo, C., & Linkermann, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00041.2016 · Cited by 217

STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling

Arimoto, K., Löchte, S., Stoner, S. A., Burkart, C., Zhang, Y., Miyauchi, S., Wilmes, S., Fan, J.-B., Heinisch, J. J., Li, Z., et al. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3378 · Cited by 210

Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies

Li, J., Li, J., Peng, Y., Du, Y., Yang, Z., & Qi, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.053 · Cited by 201

Tumor Immunity and Immunotherapy for HPV-Related Cancers

Shamseddine, A. A., Burman, B., Lee, N. Y., Zamarin, D., & Riaz, N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1760 · Cited by 203

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

Type I Interferons and Natural Killer Cell Regulation in Cancer

Müller, L., Aigner, P., & Stoiber, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00304 · Cited by 173

The added value of type I interferons to cytotoxic treatments of cancer

Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Musella, M., Manic, G., Maria, R. D., Vitale, I., & Sistigu, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1314424 · Cited by 147